You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黄医药启动欧美两项治疗晚期实体瘤或恶性血液肿瘤国际I期临床试验
阿思达克 03-29 14:40
和黄医药(HCM.US)公布,已启动两项「HMPL-306」的国际I期研究。「HMPL-306」是一种新型双重靶向异柠檬酸脱氢(酉每)(IDH)1和2突变的选择性小分子抑制剂。两项研究分别用於治疗晚期实体瘤患者及恶性血液肿瘤患者,均於美国和欧洲设立临床试验中心。

集团指,继去年下半年中国I期研究启动後,国际研究的首名患者已於今年3月25日接受给药治疗。新的研究标志集团正进一步加速和扩展全球临床研发业务。两项多中心临床试验旨在评估「HMPL-306」的安全性、耐受性、药代动力学、药效学和初步疗效。首项临床试验针对实体瘤(包括但不限於胶质瘤、软骨肉瘤或胆管癌),而第二项临床试验针对伴有IDH1和/或IDH2突变的晚期复发性或难治性恶性血液肿瘤。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account